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A successful anti-tumour immune response requires an activation
of several distinct but interacting immune effector functions
resulting in a localized cytotoxic attack. Effector T-cells have been
demonstrated in both human and animal studies to have the
capacity of mediating immune responses against certain tumours
(Rosenberg et al, 1985; Klarnet et al, 1989; Kahn et al, 1991; Hom
et al, 1991). In the murine immune system CD4+ helper T-cells can
be distinguished into either ‘Th-1’ cells that facilitate cell-medi-
ated cytotoxicity by the production of tumour necrosis factor
(TNF)-a, interlukin (IL)-2 and interferon (IFN)-a, or into ‘Th-2’
cells that stimulate B-cell growth, differentiation and antibody
production by the secretion of IL-4, IL-5, IL-6 and IL-10
(Mosmann et al, 1989). IL-4 and IL-10 may also act as
immunoregulatory cytokines since they inhibit a number of Th-1
effector functions and may block overall macrophage cytotoxicity
(Oswald et al, 1992; Sundstedt et al, 1997). Moreover, IL-10 has
been shown to suppress both IFN-g production and the anti-tumour
effector phase of IFN-g (Aruga et al, 1997; Groux et al, 1998).
Superantigens (SAg) are bacterial and viral proteins that share
the ability to activate a large number of T-cells as well as
macrophages. Bacterial SAg bind to major histocompatibility
complex (MHC) class II molecules as unprocessed proteins and
subsequently interact with a high number of T-cells expressing
particular T-cell receptor Vb chains (White et al, 1989; Janeway et
al, 1989). SAg activate both CD4+ and CD8+ T-cells and are very
potent inducers of lymphokines and monokines, as well as of T-
cell cytotoxicity (Langford et al, 1978; Andersson et al, 1992;
Dohlsten et al, 1993; Scherer et al, 1993; Dhein et al, 1995). In
order to enhance immunogenicity of tumour cells we have geneti-
cally fused the Fab region of a tumour-reactive monoclonal
antibody (mAb) with the SAg Staphylococcal enterotoxin A
(Fab–SEA) (Dohlsten et al, 1994, 1995).
Poorly immunogenic B16 melanoma cells were transfected with
the gene encoding for human colon carcinoma antigen C215 and
used to evaluate the effects of C215 Fab–SEA treatment in a
syngeneic lung metastasis model (Dohlsten et al, 1995; Rosendahl
et al, 1996). Treatment with C215 Fab–SEA fusion protein eradi-
cated 95% of pulmonary B16–C215 melanoma metastasis in fully
immunocompetent mice (Dohlsten et al, 1995; Rosendahl et al,
1996).
Recently, the systemic and local immune responses after
repeated injections of Fab–SEA were demonstrated to generate two
distinct, but coupled, immune reactions (Litton et al, 1997). TNF-
a, MIP-1a and MIP-1-b were immediately synthesized at the local
tumour site in the lung tissue in response to the primary Fab–SEA
injection. Concurrently, SEA-reactive T-cells produced high levels
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© 1999 Cancer Research Campaignof IL-2 in the spleen and began to proliferate. The primed and
expanded SEA-reactive CD4+ and CD8+ T-cells accumulated in the
tumour area in response to repeated Fab–SEA injections and
produced large amounts of the tumour suppressive cytokines IFN-g
and TNF-a. Marginal production of IL-10 was detected in the
tumour, while partial production was recorded in the spleen.
In the present study, CD4, CD8 and IL-10 knock-out (KO) mice
were used to characterize the importance of the T-cell subsets
and the regulatory role of IL-10 during Fab–SEA anti-tumour
responses, locally at the tumour site or systemically in the spleen.
This study illustrated the functional significance of both CD4+ and
CD8+ T-cells in mediating cellular infiltration, Th-1/Th-2 cytokine
release and the induction of perforin.
MATERIALS AND METHODS
Animals
C57B1/6 mice were obtained from Brommice (Ry, Denmark) and
kept under pathogen-free conditions. The mice were 8–12 weeks
of age when used in this study. CD4 and CD8 KO mice were a
kind gift from T Mak and were generated using homologous
recombination (Fung Leung et al, 1991; Rahemtulla et al, 1991)
and back-crossed to the C57B1/6 background. IL-10 KO mice
were obtained from B&K Universal Ltd, UK.
Reagents
The construction and expression of C215 Fab–SEA (Fab–SEA)
were performed as previously described (Dohlsten et al, 1994).
The fusion protein was expressed in Escherichia coli K-12 UL635
(ara-14, xyl-7, DompT, T4R) and purified on a protein G
Sepharose column (Pharmacia LKB Biotechnology), and fractions
containing Fab–SEA were passed through a PD-10 column
(Pharmacia LKB Biotechnology).
Antibodies
mAbs directed against IFN-g (XMG1.2), IL-4 (11B11), CD4, CD8,
CD11b was purchased from PharMingen (San Diego, CA, USA).
Anti-perforin mAb was purchased from Kamiya Biomedical
Company (Tukwila, WA, USA). The IL-10-reactive mAb 16E3 was
provided by Dr John Abrams DNAX Research Institute (CA, USA).
In vivo tumour therapy
C215-transfected B16-melanoma cells (1 ´ 105) in 0.2 ml phos-
phate-buffered saline (PBS) with 1% syngeneic mouse serum were
inoculated intravenously (i.v.) into the tail vein. Treatment with
one i.v. injection (0.05–50 mg) of Fab–SEA per day for 4 days was
initiated at day 5. Mice were sacrificed at day 21 and lung metas-
tases counted. To detect cellular infiltration or cytokine produc-
tion, treatment was initiated at day 18 when large lung metastases
were present. Staining for infiltration was performed at various
time points after the injections as indicated in Figure legends.
Immunohistochemistry
Cryopreserved tissue sections were stained with the saponin–
formaldehyde procedure as previously reported (Litton et al,
1994). Briefly, the sections were cut and fixed with 2% formalde-
hyde in PBS for 20 min at 20°C. The sections were incubated
overnight with anti-cytokine or anti-perforin mAb at 2 mg ml–1
with 0.1% saponin. Sections were then incubated with biotinylated
mouse absorbed rabbit anti-rat 1:500 (Vector Labs, Burlingame,
CA, USA) for 30 min, followed by an incubation for 30 min with
ExtraAvidin AP (1:2870) (Sigma). The substrate used, New
Fuchsin Red (Dako), was filtered for 10 min. For detection of
surface markers the above procedure was repeated, but without
saponin. To test the specificity of the immunohistochemistry, rele-
vant recombinant cytokines were used to block specific cytokine
staining as previously described (Litton et al, 1997).
Computer-aided image analysis
All of the cytokines detected and cellular infiltration and perforin
secretion were analysed as previously reported (Litton et al, 1997).
Briefly, each tissue was quantified using specific colour detection
to measure the amount of immunoreactivity. These detection
values were then used for assessing all cytokines, cell phenotypes
and controls. The standard non-paired two-tailed Student’s t-test
was used to evaluate and compare the therapeutical observations
and the immunological results obtained from image analysis.
Tumour growth inhibition in vitro
C215-transfected B16 melanoma cells (1700 cells per well) were
cultured in the presence of 5 mg IFN-g and increasing amounts
of IL-10. The cell viability was analysed in a MTT (3-(4,5-
dimethylthiazal-2-yl)-2,5-diphenyl tetrazolium bromide) assay
after 72 h according to a standard protocol (Rosendahl et al,
1998b).
RESULTS
Tumour therapy with C215 Fab–SEA in CD4- and
CD8-deficient mice
We have earlier demonstrated that four daily injections (1 injection
per day for 4 days) of Fab–SEA significantly (P > 0.01) reduced
the number of B16-C215 melanoma lung metastases (Rosendahl
et al, 1996). In order to dissect the role of CD4+ and CD8+ T-cells
during the therapy, CD4 KO or CD8 KO mice carrying B16-C215
melanoma were treated with Fab–SEA. Repeated administration
of Fab–SEA significantly reduced the number of B16–C215-trans-
fected melanoma cells (P < 0.05) in immunocompetent animals
(Figure 1). In contrast, both CD4 KO and CD8 KO mice had a
significant impairment in anti-tumour therapy (Figure 1). Most
interestingly, CD8 KO mice induced a stronger anti-tumour
response after Fab–SEA therapy when compared to CD4 KO
(Figure 1). These results demonstrate the both CD4+ and CD8+ T-
cells are required to perform optimal Fab–SEA tumour therapy.
Spontaneous Th-2 cytokine production prior to therapy
in CD8 KO mice
In normal and CD4 KO mice no infiltration of IL-4- or IL-10-
producing T-cells was detected prior to Fab–SEA treatment
(Figure 2). In contrast, cells that spontaneously produced both IL-
4 and IL-10 were observed in the tumour area in untreated CD8
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only a small number of IL-4- or IL-10-producing cells were
detected in normal mice in spleen or in the lung (Figure 3A–D). In
CD4 KO mice a marginal increase of IL-4- or IL-10-producing
cells was recorded 24 h after the injection (Figure 3A–D). In sharp
contrast, the frequency of IL-4- and IL-10-producing cells was
two- to tenfold higher in CD8 KO compared to normal mice in
both the tumour and spleen, but especially in the spleen (Figure
3A–D). These results suggest that CD8+ T-cells may regulate the
fine-tuning of cytokine production after Fab–SEA treatment.
The functional importance of CD4+ T-cells
We recently demonstrated that IFN-g-producing tumour-infil-
trating lymphocytes (TIL) infiltrate the tumour area in immuno-
competent animals given four repeated injections of Fab–SEA
(Dohlsten et al, 1995a). In order to determine which T-cell subset
was required to obtain maximal infiltration of TIL, CD4 KO and
CD8 KO mice were treated with Fab–SEA, and the cell infiltration
as well as the IFN-g production was monitored. Local IFN-g
production in normal mice was detected 2 h after the fourth injec-
tion and maximal production was recorded after 4 h (Figure 4A).
Even 24 h after the fourth injection massive IFN-g production was
detected (Figure 4A). Similar to normal mice, CD8 KO mice
induced substantial IFN-g production in response to the fourth
injection (Figure 4A). In sharp contrast, only marginal infiltration
of IFN-g-producing cells was recorded in CD4 KO mice (Figures
4A and 5A,B). In addition, the number of tumour-infiltrating CD8+
T-cells was significantly reduced in CD4 KO mice after repeated
Fab–SEA injections (Figure 4D). In both CD8 KO and CD4 KO
mice the macrophage infiltration was reduced threefold compared
to normal mice (Figure 4B). These results suggest that the IFN-g
production induced by Fab–SEA tumour therapy and the induction
of an inflammatory milieu is dependent on CD4-reactive infil-
trating TIL.
Perforin secretion is induced after repeated Fab–SEA
therapy
We recently demonstrated that Fab–SEA-based therapy of B16-
C215 melanoma requires release of perforin (Rosendahl et al,
1998b). In order to investigate if Fab–SEA induced local release of
perforin, lung metastases and spleen were analysed by staining for
perforin after repeated Fab–SEA injections. Both locally in the
tumour area and in the spleen, perforin secretion peaked after the
third injection of Fab–SEA (Figure 6 A,B). Importantly, after three
injections of Fab–SEA, CD8 KO mice had a significant reduction
in the number of perforin-secreting cells (Figure 6C). These results
suggest that optimal therapy of tumours sensitive to perforin
requires an intact CD8 compartment.
Improved therapeutic efficacy in the absence of IL-10
We have recently demonstrated that elimination of B16-C215
melanoma is dependent on IFN-g production (Rosendahl et al,
1998b). Since IL-10 has been demonstrated to inhibit the produc-
tion and effector phase of IFN-g both directly (Aruga et al, 1997;
Sundstedt et al, 1997) and indirectly, by modulation of the expres-
sion of MHC class II and co-stimulatory molecules (de Waal
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Figure 1 Impaired Fab–SEA tumour therapy in CD4 and CD8 KO mice.
The figure represents the reduction in B16–C215 tumour metastasis in
normal C57B1/6, CD4 and CD8 KO mice. Animals were inoculated with
1 ´ 105 B16–C215 melanoma cells. On days 5–8, mice were treated i.v. with
50 mg of Fab–SEA. Lung metastases were counted on day 21. The number
of lung metastases in untreated normal C57B1/6, CD4 and CD8 KO mice
was 103, 108 and 77 respectively. Each group contained seven animals.
Data are presented from one out of three similar experiments. The mean ±
s.e.m. are shown. Statistical significance was analysed by Mann–Whitney
U-test. *indicates 0.05 < P > 0.01; **indicates 0.01 < P > 0.001; ***indicates 
P < 0.001
AB
Figure 2 Spontaneous Th-2 cytokine production prior to therapy in CD8 KO mice. The figure illustrates (A) IL-4- and (B) IL-10-producing cells stained by
immunohistochemistry at the local tumour site prior to Fab–SEA therapy. Animals were treated with a single i.v. injection of 50 mg Fab–SEA on day 18 and
sacrificed as indicated in figure. Data are presented from one out of two similar experiments362 MJ Litton et al
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Figure 3 Th-2 cytokine production locally in the tumour area. The production of IL-4 (A, C) and IL-10 (B, D) is quantified using computer-aided image analysis
as a percentage of total lung (A, B) or spleen (C, D) tissue area. Animals were treated with four i.v. injections of 50 mg Fab–SEA on day 18–21 and sacrificed as
indicated in figure. Data are presented from one out of two similar experiments. The mean ± s.e.m. are shown
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Figure 4 Impaired infiltration of effector cells in CD4 KO mice. The figure illustrates the IFN-g production (A), infiltration of macrophages (B), CD4+ (C) and
CD8+ (D) quantified by computer-aided image analysis as a percentage of the total tumour lung tissue area. Animals were treated with four i.v. injections of
50 mg Fab–SEA on day 18–21 and sacrificed as indicated in the figure. Data are presented from one out of two similar experiments. The mean ± s.e.m. are
shownMalefyt et al, 1991a, 1991b, Willems et al, 1994) we investigated
if the therapeutic efficacy could be improved in IL-10 KO mice.
When C215-transfected B16 melanoma cells were cultured in vitro
in the presence of IFN-g alone, marked tumour growth inhibition
was recorded (Rosendahl et al, 1998b). In contrast, when IFN-g
and IL-10 both were present in culture, partial recovery of the
B16-melanoma cell growth was noted, indicating that IL-10
modulated the growth inhibitory effects exhibited by IFN-g
(Figure 7A). Following treatment of B16-C215 lung metastasis
with four daily injections of Fab–SEA, strong anti-tumour effects
(P > 0.01) were seen in the IL-10 KO mice at doses from 0.05 mg
to 50 mg (Figure 7B). Most importantly, at low doses (0.05–0.5 mg
Fab–SEA per injection) significantly improved therapy (P > 0.05)
was detected in IL-10 KO mice compared to wild-type mice
Targeted superantigen tumour therapy in T-cell-deficient mice 363
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AB
Figure 5 The functional importance of CD4+ T-cells. The figure illustrates cellular production of IFN-g stained by immunohistochemistry in normal C57B1/6
mice (A) or in CD4 KO mice (B). Animals were treated with four i.v. injections of 50 mg Fab–SEA on day 18–21 and sacrificed as indicated in figure. Data are
presented from one out of two similar experiments
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Figure 6 Perforin expression is induced after Fab–SEA therapy. The figure illustrates perforin expression in C57B1/6 mice stained by immunohistochemistry in
the spleen (A) and lung (B) quantified using computer-aided image analysis as a percentage of the total tissue area. Local perforin expression was compared in
CD4 or CD8 KO mice versus C57B1/6 mice in the tumour lung tissue during the peak of secretion (C). Animals were treated with 1–4 i.v. injections of 50 mg
Fab–SEA on day 18–21, as indicated by arrows. Data are presented from one out of two similar experiments. The mean ± s.e.m. are shown(Figure 7B). This suggests that presence of IL-10 locally in the
tumour area or in systemic blood limits the therapeutic efficacy of
SAg–mAb fusion protein-based therapy.
DISCUSSION
Mature T-cells expressing the T-cell receptor ab heterodimer can
be divided into two major subsets based on their exclusive expres-
sion of CD4 or CD8 surface molecules; these subsets of cells will
bind to antigens presented in the context of MHC class II or class I
molecules respectively. SAg have, in contrast to conventional
peptide antigens, a unique capacity of activating both subsets of T-
cells (Herrmann et al, 1990; Dohlsten et al, 1990). In fact, it has
been demonstrated previously that both CD4+ and CD8+ T-cells are
recruited to the tumour area in response to antibody-targeted SAg
tumour therapy (Dohlsten et al., 1995a; Litton et al, 1996, 1997;
Rosendahl et al, 1998a). However, both subsets have the potential
to regulate helper activity as well as cytotoxic functions. It is
therefore essential to investigate effector mechanisms by each
subset during the course of Fab–SEA activation.
Similar to previous studies, repeated administration of Fab–
SEA, given daily for 4 consecutive days, significantly (P < 0.01)
reduced the number of B16–C215 pulmonary melanoma metas-
tasis in immunocompetent animals when compared to untreated
animals (Rosendahl et al, 1996). It was discovered that mice that
lacked CD4+ or CD8+ T-cells had a significantly impaired thera-
peutic response. The results showed that CD8 KO mice mounted a
stronger anti-tumour response after Fab–SEA therapy than CD4
KO mice. These results are in line with the previous findings that
Fab–SEA therapy was unsuccessful in severe combined immune
deficient (SCID) mice and nude mice, deficient of T-cells (Litton
et al, 1996). Thus, T-cells are important mediators in SAg-targeted
therapy. However, in the current study, neither CD4+ nor CD8+ T-
cells alone were able to effectively eradicate the tumours. This
strongly suggests that the T-cells subsets collaborate to induce the
appropriate anti-tumour response. Similar findings have been
reported previously in other studies with murine and human
tumours, but the underlying mechanisms have not been well char-
acterized (Kern et al, 1986).
Spontaneous cytokine production at the local tumour site prior
to Fab–SEA therapy was observed in CD8 KO mice, but not in
CD4 KO or normal C57B1/6 mice. CD8+ KO mice expressed cells
that produced IL-4 and IL-10 in areas that were in close contact
with the pulmonary tumours and in numerous cells in the spleen.
These cytokine-producing cells were not detected prior to therapy
in the other investigated animals. These results suggest that CD8+
T-cells have the ability to alter the cytokine production of CD4+ T-
cells both at the local tumour site and the lymphoid organs. A
possible candidate cell for the IL-4 synthesis could be CD4+
NK1.1+ T-cells that are known to produce IL-4 (Yoshimoto et al,
1994). The tendency of CD8 KO mice to produce Th-2 cytokines
in the tumour vicinity remained after Fab-SEA therapy. In
contrast, in normal C57B1/6 and CD4 KO mice IL-4- and IL-10-
producing cells were only detected in the spleen after four injec-
tions of Fab–SEA, and were never detectable at the tumour site.
These results combined with the reduced anti-tumour response
would imply that in CD8 KO mice the tumour therapy was
impaired due to the release of regulatory Th-2-type cytokines. This
pattern is also seen during helminth infections where early IL-4
drives the response towards a Th-2-type response (Sher et al,
1992; Yoshimoto et al, 1994). IL-10 has been shown to down-
regulate T-cell immune responses by various mechanisms. It may
inhibit and down-regulate monocyte MHC class II expression as
well as interfere with antigen presentation (Fiorentino et al, 1991),
inhibit the up-regulation of co-stimulatory molecules (Ding et al,
1993) and suppress the cytotoxicity of macrophages (Giovarelli et
al, 1995). In addition, it was recently demonstrated that T-cell
receptor triggering in the presence of IL-10 inhibited IFN-g
production in freshly isolated CD4+ T-cells (Groux et al, 1996)
and down-regulated the expression of granzyme B (Fitzpatrick et
al, 1996). In vivo neutralization of IL-10 after SEA stimulation
strongly augmented the production of the tumouricidal cytokines
364 MJ Litton et al
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Figure 7 IL-10 counteracts the IFN-g-induced growth inhibition of B16-melanoma. C215-transfected B16 melanoma cells (1.7 ´ 103) were cultured in the
presence of IFN-g (5 ng ml–1) or the combination of IFN-g (5 ng ml–1) and increasing amounts of IL-10 in vitro. After 72 h the viability was detected in MTT-assay.
The values indicate a mean from a triplicate. One representative experiment out of three. (C) Animals were inoculated with 1 ´ 105 C215-transfected B16
melanoma cells. At day 4–7 the mice were treated with 50 mg Fab–SEA i.v. Lung metastases were counted at day 21. Each group contained seven animals.
One out of two similar experiments. The significance was analysed by the Mann–Whitney U-test. *0.05 < P > 0.01; **0.01< P > 0.001; ***P < 0.001. The
mean ± s.e.m. are shown
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NS NS BIFN-g and TNF-a (Sundstedt et al, 1997). Moreover, Aruga et al
(1997) demonstrated that in vivo neutralization of IL-10 strongly
improved the anti-tumour response. In line with these experiments,
we recorded elevated and prolonged IFN-g production in IL-10
KO mice (data not shown). More importantly, significantly
improved therapeutic efficacy was noted in IL-10 KO mice
compared to normal mice. Thus, the low level of IL-10 induced
after repeated stimulation with Fab–SEA seems to interfere with
targeted SAg anti-tumour therapy in normal mice. It is tempting to
speculate that the markedly elevated IL-10 levels recorded in CD8
KO mice in the tumour vicinity may in part account for the
reduced therapeutic efficacy. Whether this is related to reduced
expression of granzyme B remains to be investigated.
After four injections of Fab–SEA therapy the tumour infiltration
of macrophages, CD4+ and CD8+ T-cells was markedly increased
in immunocompetent mice. In contrast, the number of tumour-
infiltrating macrophages was significantly reduced in both CD4
and CD8 KO mice after repeated Fab–SEA injections. In addition,
mice deficient for CD4+ T-cells had a severe reduction in the
number of CD8+ TIL compared to immunocompetent mice. These
results imply that CD4+ T-cells are necessary for the recruitment of
CD8+ TIL after therapy. This is in accordance with what others
have found in allograft transplant rejection studies where mice that
were deficient in CD4+ T-cells were unable to reject transplants,
even though these knockout mice had cytotoxic capabilities
(Krieger et al, 1996). In other settings, CD4+ T-cells have been
shown to be essential in preventing the exhaustion of CD8+
effector T-cells during a high viral load of lymphocytic chorio-
meningitis virus (LCMV) (Battegay et al, 1994). In line with these
experiments, we recently demonstrated augmented CD8+ prolifer-
ation, IFN-g production, CTL activity and tumour cell eridication
when Fab–IL-2 was injected in conjunction with Fab–SEA
(Rosendahl et al, 1999). These results suggest that the anergic
CD4+ T-cells fail to produce IL-2 in levels required to activate the
responsive ‘memory’ CD8+ T-cells. Thus as Lee et al (1992)
demonstrated, SAg fail to induce CD4+ memory, while responsive
CD8+ T-cells’ memory cells are induced (Coppola et al, 1997). It is
tempting to speculate that the anergic CD4+ T-cells fail to deliver
activating signals to the CD8+ T-cells, which then fail to perform
anti-tumour effector mechanisms.
It was also demonstrated in the present study that CD4 KO mice
were unable to produce IFN-g, while CD8 KO mice and normal
C57B1/6 mice generated significant numbers of IFN-g-producing
cells in response to therapy. This result, in combination with the
lack of effective therapy observed in these mice, suggests that
IFN-g is an important mediator in the overall cytostatic anti-
tumour response. Macrophages are known to mediate strong
tumouricidal effects and depend on IFN-g as a priming factor for
tumour cytotoxicity (Pace et al, 1981; Schreiber, 1984). In addi-
tion, we recently demonstrated that therapy of the B16 melanoma
strongly depends on release of IFN-g (Rosendahl et al, 1998b).
Therefore, IFN-g probably exerts both direct and indirect anti-
tumour effects.
A primary pathway for T-cell-mediated cytotoxicity is through
perforin granular exocytosis. It has been illustrated that perforin
KO mice have impaired cytotoxicity of CTL and natural killer
cells (Kagi et al, 1994; Rosendahl et al, 1998b). In addition, we
recently demonstrated that Fab–SEA-based therapy of B16-C215
melanoma is compromised in perforin KO mice (Rosendahl et al,
1998b). We now demonstrate that Fab–SEA-treated normal
C57B1/6 mice display perforin secretion in the vicinity of tumour
cells. In contrast, perforin secretion was strongly reduced in CD8
KO mice, and moderately in CD4 KO mice. This strengthens the
notion that perforin secretion is important in the tumour eradica-
tion process and that this is dependent on an appropriate CD4+ and
CD8+ T-cell interaction. It was illustrated in CD8 KO mice that the
majority of perforin secretion was derived from CD8+ T-cells. CD4
KO mice have an expanded population of CD4–CD8–T-cell
receptor a/b+ (double negative) T-cells (Fung Leung et al, 1991)
that possess suppressor characteristics (Schmidt Wolf et al, 1992).
It is possible that this accounts for the low amount of perforin
secretion in these animals. Since the number of tumour-infiltrating
CD8+ T-cells were reduced in mice lacking CD4+ T-cells, it is diffi-
cult to determine if CD4+ T-cells contribute to the induction of
perforin or to the regulation of CTL infiltration.
The results in this study have demonstrated that CD4+ T-cells
provide help in recruiting CD8+ T-cells and activating tumouri-
cidal macrophages through IFN-g production. CD8+ T-cells
initially suppressed a spontaneous prominent Th-2 response
present in mice with pulmonary melanoma micrometastases, and
then after Fab–SEA therapy became perforin-secreting effector
cells at the local tumour site. Thus, during immunotherapy, both
CD4+ and CD8+ T-cells collaborate to generate multiple anti-
tumour effects to induce a maximized anti-tumour immune
response.
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